296 related articles for article (PubMed ID: 25895457)
1. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. The expression and correlation between the transcription factor FOXP1 and estrogen receptors in epithelial ovarian cancer.
Hu Z; Zhu L; Tan M; Cai M; Deng L; Yu G; Liu D; Liu J; Lin B
Biochimie; 2015 Feb; 109():42-8. PubMed ID: 25500588
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Wang L; Mao Y; Du G; He C; Han S
Tumour Biol; 2015 Apr; 36(4):2465-72. PubMed ID: 25663457
[TBL] [Abstract][Full Text] [Related]
5. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
[TBL] [Abstract][Full Text] [Related]
6. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
8. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
9. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
Han GH; Yun H; Chung JY; Kim JH; Cho H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
[TBL] [Abstract][Full Text] [Related]
11. Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
Xie X; Yang M; Ding Y; Yu L; Chen J
Oncol Rep; 2017 Dec; 38(6):3297-3308. PubMed ID: 29039544
[TBL] [Abstract][Full Text] [Related]
12. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
[TBL] [Abstract][Full Text] [Related]
13. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
14. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer.
Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C
Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105
[TBL] [Abstract][Full Text] [Related]
15. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
16. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
17. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
Du J; Li B; Fang Y; Liu Y; Wang Y; Li J; Zhou W; Wang X
BMC Cancer; 2015 Jul; 15():536. PubMed ID: 26198101
[TBL] [Abstract][Full Text] [Related]
19. The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer.
Xi Q; Huang M; Wang Y; Zhong J; Liu R; Xu G; Jiang L; Wang J; Fang Z; Yang S
Tumour Biol; 2015 Jul; 36(7):4939-48. PubMed ID: 25910705
[TBL] [Abstract][Full Text] [Related]
20. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
